Study of vedotin for advanced bile duct cancer after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called vedotin for people with advanced bile duct or gallbladder cancer that has grown after at least one prior treatment. The drug is given as an infusion and works by targeting cancer cells with a specific marker, potentially slowing or shrinking the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced bile duct or gallbladder cancer that has spread or come back.
- Your tumor tests positive for a protein called EGFR.
- You have already received at least one line of cancer treatment.
- You are able to care for yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You have at least one measurable tumor on a CT or MRI scan.
- Your blood counts, liver, and kidney function are within acceptable limits.
- You have no severe complications like active bleeding, bowel blockage, or fever from infection.
- You agree to use contraception during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
This trial tests whether adding the experimental drug becotatug vedotin to standard chemotherapy and radiation therapy can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma. It may help shrink the tumor or slow its growth.
This trial tests a new drug called becotatug vedotin (MRG003) for patients with advanced liver cancer that has progressed despite previous immunotherapy. The drug is designed to target cancer cells while potentially causing less harm to healthy tissue.
This study tests a combination of two new drugs for advanced colorectal cancer. One drug targets a protein on cancer cells (EGFR) and delivers a chemotherapy-like agent directly to the tumor, while the other boosts the immune system to fight cancer. Participation may offer a new option if standard treatments have stopped working.
This trial tests a combination of four drugs (adebrelimab, apatinib, gemcitabine, and cisplatin) as a first treatment for people with advanced or metastatic bile duct cancer that cannot be removed by surgery. The goal is to see if this combination helps shrink or control the cancer.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.